COVID-19 outbreak, caused by severe acute respiratory syndrome (SARS)-CoV-2
coronavirus has become an urgent health and economic challenge. Diabetes is a risk factor …

Glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1)
are the two primary incretin hormones secreted from the intestine on ingestion of various …

Estrogen affects proliferation and migration of different skin components, thus influencing
wound healing processes. The human keratinocyte cell line NCTC 2544 has been used to …

Gliptins have been recently shown to conquer neuronal degeneration in cell cultures via
modulating glucagon‐like peptide (GLP)‐1. This peptide produced in the gut not only …

We performed a review of the literature to determine whether the dipeptidyl peptidase-4
inhibitors (DPP4-I) may have the capability to directly and positively influence diabetic …

Advanced glycation end products (AGEs) consist of heterogenous group of macroprotein
derivatives, which are formed by non-enzymatic reaction between reducing sugars and …

Abstract Dipeptidyl-peptidase-4 (DPP-4) inhibitors are a relatively new class of non-insulin
glucose-lowering agents, belonging to the incretin family, which are able to improve …

Advanced glycation end products (AGEs) and their receptor (RAGE) play a role in diabetic
nephropathy. We have recently found that linagliptin, an inhibitor of dipeptidyl peptidase-4 …

In type 2 diabetes, anti-thrombotic management is challenging, and current anti-platelet
agents have demonstrated reduced efficacy. Old and new anti-diabetic drugs exhibited …

The dipeptidyl peptidase-4 inhibitor vildagliptin (Galvus®) is approved for use as
monotherapy and combination therapy in type 2 diabetes mellitus. A fixed-dose combination …